Request Demo

Last update 31 Aug 2025

Hydrochlorothiazide

Last update 31 Aug 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryHydrochlorothiazide, a small molecule drug, targets the NCC co-transporter as an inhibitor, exhibiting an assortment of therapeutic effects. The drug, first approved on February 12th, 1959, and originally developed by Novartis, is primarily used to treat edema, hypertension, and kidney calculi, and may be used to manage diabetes insipidus. Hydrochlorothiazide operates by obstructing the reabsorption of sodium and chloride ions in the distal convoluted tubule of the kidney, producing augmented excretion of water and electrolytes. This, in turn, reduces edema and lowers blood pressure. However, while the drug can be beneficial, it can also be associated with a range of side effects, including electrolyte imbalances and low blood pressure, and should be used with caution in patients with severe kidney disease. It is of utmost importance to only use Hydrochlorothiazide under the guidance of a healthcare provider, and patients should be carefully monitored for any adverse effects. In summary, Hydrochlorothiazide presents a diverse array of benefits for managing numerous conditions, yet the appropriateness of its use should be carefully tailored to each individual patient.

Drug Type

Small molecule drug

Synonyms

HCTZ, Hydrochlorothiazide (JP17/USP/INN), 氢氯噻嗪微片

+ [11]

Target

NCC

Action

inhibitors

Mechanism

NCC inhibitors(Thiazide-sensitive sodium-chloride cotransporter inhibitors)

Therapeutic Areas

Nervous System DiseasesCardiovascular DiseasesEndocrinology and Metabolic Disease+ [2]

Active Indication

Nephrotic SyndromeDiabetes InsipidusEdema+ [2]

Inactive Indication

Diabetes Mellitus, Type 2Essential Hypertension

Originator Organization

Novartis Pharma AG

Active Organization

Beijing CoSci Med-Tech Co., Ltd.

Phebra Pty Ltd.

Yichang Humanwell Pharmaceuticals Co., Ltd.

+ [5]

Inactive Organization

Novartis AG

Novartis Pharmaceuticals Canada, Inc.

Novartis Pharmaceuticals Corp.

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (12 Feb 1959),

Hypertension

Regulation-

Structure/Sequence

Molecular FormulaC7H8ClN3O4S2

InChIKeyJZUFKLXOESDKRF-UHFFFAOYSA-N

CAS Registry58-93-5

254

Clinical Trials associated with Hydrochlorothiazide

CTR20252112

/ RecruitingNot Applicable

氢氯噻嗪微片在中国健康受试者中随机、开放、两制剂、单次给药、双周期、交叉的空腹及餐后状态下的生物等效性试验

[Translation] A randomized, open-label, two-dose, single-dose, two-period, crossover bioequivalence study of hydrochlorothiazide microtablets in Chinese healthy subjects under fasting and fed conditions

主要目的：以LABORATOIRES JUVISE PHARMACEUTICALS的氢氯噻嗪片(商品名：ESIDREX®，规格：25 mg/片)为对照药，以北京科信必成医药科技发展有限公司委托河南力芯联创生物医药科技有限公司生产的氢氯噻嗪微片(规格：5 mg/片)为试验药，考察餐后和空腹条件下试验药与对照药在健康受试者中的药代动力学参数，评价两制剂的生物等效性。次要目的：评价中国健康受试者单次空腹及餐后口服试验药氢氯噻嗪微片和对照药氢氯噻嗪片后的安全性。

[Translation]

Primary objective: Using hydrochlorothiazide tablets (trade name: ESIDREX®, specification: 25 mg/tablet) of LABORATOIRES JUVISE PHARMACEUTICALS as the control drug and hydrochlorothiazide microtablets (specification: 5 mg/tablet) produced by Henan Lixin Lianchuang Biopharmaceutical Technology Co., Ltd. commissioned by Beijing Kexin Bicheng Pharmaceutical Technology Development Co., Ltd. as the test drug, the pharmacokinetic parameters of the test drug and the control drug in healthy subjects under fed and fasting conditions were investigated to evaluate the bioequivalence of the two preparations. Secondary objective: To evaluate the safety of Chinese healthy subjects after a single oral administration of the test drug hydrochlorothiazide microtablets and the control drug hydrochlorothiazide tablets on an empty stomach and after a meal.

Start Date20 Jun 2025

Sponsor / Collaborator

Beijing CoSci Med-Tech Co., Ltd.

NCT07020104

/ RecruitingNot ApplicableIIT

The Role of Skin Sodium Accumulation in Chronic Kidney Disease

This project consists of four substudies: a cohort study (A) and a sodium intake intervention (B) and a sodium excretion intervention (C) and a water intervention study (D).
The main objective of the cohort study (A) is to investigate the prognostic implications of tissue sodium accumulation in CKD patients. The primary objective of the sodium intervention studies is to study the effect of high and low sodium intake (B) and increased renal sodium excretion (C) on tissue sodium content. The main objective of the water intervention study (D) is to investigate the effect of increased and habitual water intake on tissue sodium content and transepidermal water loss.

Start Date07 Jan 2025

Sponsor / Collaborator

Nierstichting Nederland

CTR20243533

/ CompletedNot Applicable

氢氯噻嗪片（25mg）在中国健康受试者中空腹和餐后给药条件下随机、开放、单剂量、两序列、两周期、双交叉生物等效性试验

[Translation] A randomized, open-label, single-dose, two-sequence, two-period, double-crossover bioequivalence study of hydrochlorothiazide tablets (25 mg) in Chinese healthy subjects under fasting and fed conditions

主要研究目的：按有关生物等效性试验的规定，选择Laboratoires Juvise Pharmaceuticals为持证商的氢氯噻嗪片（商品名：ESIDREX，规格：25mg）为参比制剂，对辰欣药业股份有限公司生产并提供的受试制剂氢氯噻嗪片（规格：25mg）进行空腹和餐后给药人体生物等效性试验，比较受试制剂中药物的吸收速度和吸收程度与参比制剂的差异是否在可接受的范围内，评估两种制剂在空腹和餐后给药条件下的生物等效性。次要研究目的：观察健康志愿受试者口服受试制剂氢氯噻嗪片（规格：25mg）和参比制剂氢氯噻嗪片（商品名：ESIDREX，规格：25mg）的安全性。

[Translation]

Main research purpose: According to the relevant provisions of bioequivalence test, hydrochlorothiazide tablets (trade name: ESIDREX, specification: 25mg) of Laboratoires Juvise Pharmaceuticals as the licensee were selected as the reference preparation, and the test preparation hydrochlorothiazide tablets (specification: 25mg) produced and provided by Chenxin Pharmaceutical Co., Ltd. were subjected to human bioequivalence test on fasting and postprandial administration, to compare whether the absorption rate and degree of the drug in the test preparation were within the acceptable range with the reference preparation, and to evaluate the bioequivalence of the two preparations under fasting and postprandial administration conditions. Secondary research purpose: To observe the safety of oral administration of the test preparation hydrochlorothiazide tablets (specification: 25mg) and the reference preparation hydrochlorothiazide tablets (trade name: ESIDREX, specification: 25mg) by healthy volunteers.

Start Date24 Oct 2024

Sponsor / Collaborator

Cisen Pharmaceutical Ltd.

100 Clinical Results associated with Hydrochlorothiazide

100 Translational Medicine associated with Hydrochlorothiazide

100 Patents (Medical) associated with Hydrochlorothiazide

12,246

Literatures (Medical) associated with Hydrochlorothiazide

01 Dec 2025·Water Research X

Micropollutants removal, residual risk, and costs for quaternary treatments in the framework of the Urban Wastewater Treatment Directive

Author: Antonelli, Manuela ; Piraldi, Sara ; Ianes, Jessica ; Cantoni, Beatrice

The revised Urban Wastewater Treatment Directive (UWWTD) imposes stringent regulations for the removal of micropollutants from urban wastewater treatment plants.The analyses conducted in this study are based on current knowledge extrapolated from literature WWTPs, to investigate the occurrence, removal and environmental risk related to the 12 target micropollutants: Amisulpride, Benzotriazole, 4,5-Methylbenzotriazole, Carbamazepine, Clarithromycin, Citalopram, Candesartan, Diclofenac, Hydrochlorothiazide, Irbesartan, Metoprolol, and Venlafaxine.The goal is to provide valuable insights into the challenges and opportunities associated with implementing quaternary treatment processes to comply with the UWWTD.It indicate that the conventional biol. treatment is insufficient, with median removal rates below 50% for most target micropollutants (except for Benzotriazole and Irbesartan).The implementation of quaternary treatment processes, namely ozonation and activated carbon adsorption, significantly enhances WWTP micropollutants removal, with median removal efficiencies exceeding 80% for all the target micropollutants, with Candesartan being the most recalcitrant.Environmental risk assessment reveals that some micropollutants pose a significant threat to aquatic ecosystems even with 80% removal efficiency (Irbesartan, Candesartan, Diclofenac, and Venlafaxine), while others do not pose a risk even at WWTP influent concentrations (4,5-Methylbenzotriazole, Hydrochlorothiazide, Amisulpride, Citalopram, and Metoprolol).Economic anal. shows that the selection of specific operating parameter values significantly impacts the cost of each treatment process, changing the economic feasibility ranking of the different treatment options.

01 Nov 2025·Current Drug Safety

Diuretics-Induced Acute Pancreatitis: Case Series with a Review of the Literature

Review

Author: Patel, Lalitkumar B. ; Patel, Vahin B ; Patel, Dhruvkumar M. ; Patel, Mukundkumar V. ; Patel, Dhara K. ; Patel, Maitri M.

Background::

Although diuretic-induced Acute Pancreatitis (AP) cases are typically mild to moderate, severe and potentially fatal occurrences can arise.

Case Series and Literature Review::

We have, herein, presented a series of diuretic-induced AP cases from March 2018 to February 2024 of a 54-year-old woman treated with chlorthalidone, a 45-year-old male treated with hydrochlorothiazide, and a 48-year-old male treated with frusemide. The literature search has identified 26 cases published to date, 10 from frusemide and 16 from thiazide diuretics. The Naranjo adverse reaction probability scale has categorized all three drugs as “probable”. All cases have responded to conservative treatment and cessation of the offending drug. Various mechanisms, such as hypersensitization, ischemia, direct cytotoxic effects, hypercalcemia, and dose-dependent idiosyncrasy, have been found to lead to intrapancreatic activation of pancreatic enzymes, resulting in drug-induced AP.

Conclusion::

Further research into the mechanisms and genetic factors contributing to diureticinduced AP is essential for enabling early diagnosis and management of diuretic-induced AP.

01 Nov 2025·AMERICAN HEART JOURNAL

Loop and thiazide diuretics and outcomes in heart failure with preserved ejection fraction

Article

Author: Thorvaldsen, Tonje ; Hage, Camilla ; Guidetti, Federica ; Savarese, Gianluigi ; Pitt, Bertram ; Szabó-Söderberg, Barna ; Lund, Lars H ; Benson, Lina

BACKGROUND:

Trials in heart failure with preserved ejection fraction (HFpEF) frequently apply baseline diuretic use as enrichment criterion. However, the role of thiazides and loop diuretic dose for enrichment is unclear. We aimed to assess baseline loop and thiazide diuretic use, loop diuretic dose, and associations with cardiovascular (CV) outcomes in HFpEF.

METHODS:

We performed a post-hoc analysis of TOPCAT-Americas. The primary outcome was CV death and total hospitalizations for heart failure (HHF).

RESULTS:

1765 patients were followed for a median of 2.9 years. At baseline, loop diuretic monotherapy was used in 67%, thiazide monotherapy in 10% and the combination in 12%. Loop diuretic monotherapy and combined loop+thiazide diuretic treatment were associated with higher risk of the primary outcome (HR 1.59, 95% CI 1.23-2.07, P < .001; and HR 2.07, 95% CI 1.55-2.76, P < .001 respectively), as well as first HHF, total HHFs and the composite of first HHF or CV death. Only combined loop+thiazide diuretic therapy was associated with CV death alone (HR 1.85, 95% CI 1.13-3.04, P = .015). For all above endpoints, the combined diuretic therapy was associated with greater risk than loop diuretics alone. Thiazide monotherapy was not associated with any endpoints. Higher baseline loop diuretic doses were associated with higher risk of all outcomes.

CONCLUSION:

In HFpEF, baseline use and higher doses of loop diuretics were associated with higher risk of CV death and total HHFs. Thiazide alone was not associated with any endpoints, but when added to loop diuretics it was associated with additional risk for all outcomes.

News (Medical) associated with Hydrochlorothiazide

29 Aug 2025

·www.einpresswire.com

January - March 2021 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)

Addyi (flibanserin) Drug hypersensitivity The "Contraindications", "Warnings and Precautions", "Adverse Reactions", and "Medication Guide" sections of the labeling were updated in September 2021 to include hypersensitivity reactions. Addyi labeling Glucagon-like peptide-1 (GLP-1) analogues Adlyxin (lixisenatide) Bydureon (exenatide) Bydureon BCise (exenatide) Byetta (exenatide) Ozempic (semaglutide) Rybelsus (semaglutide) Saxenda (liraglutide) Soliqua (insulin glargine and lixisenatide) Trulicity (dulaglutide) Victoza (liraglutide) Xultophy (insulin degludec and liraglutide) Drug-induced liver injury The "Adverse Reactions" section of the liraglutide and dulaglutide labeling was updated in June 2022 to include information about elevations of liver enzymes. Example: Trulicity labeling FDA determined that no action is necessary at the time for lixisenatide, exenatide, and semaglutide based on available information. Alcohol-based hand sanitizers Exposure via inhalation FDA determined that no action is necessary at the time based on available information. A FDA Drug Safety Communication was issued on June 16, 2021. Amlodipine and Levamlodipine Products Azor (amlodipine and olmesartan medoxomil ) Caduet (amlodipine besylate and atorvastatin calcium) Conjupri (levamlodipine maleate) Consensi (amlodipine besylate and celecoxib) Exforge (amlodipine and valsartan) Exforge HCT (amlodipine/valsartan and hydrochlorothiazide) Lotrel (amlodipine besylate and benazepril hydrochloride) Katerzia (amlodipine benzoate) Norvasc (amlodipine besylate) Prestalia (amlodipine besylate and perindopril arginine) Tribenzor (amlodipine besylate/olmesartan medoxomil and hydrochlorothiazide) Twynsta (amlodipine and telmisartan) Non-cardiogenic pulmonary edema FDA determined that no action is necessary at the time based on available information. Avonex (interferon beta-1a) Betaseron (interferon beta-1b) Extavia (interferon beta-1b) Plegridy (pegylated interferon beta-1a) Rebif (interferon beta-1a) Injection site abscess FDA is evaluating the need for regulatory action. Bavencio (avelumab) Imfinzi (durvalumab) Keytruda (pembrolizumab) Libtayo (cemiplimab-rwlc) Opdivo (nivolumab) Tecentriq (atezolizumab) Scleroderma FDA determined that no action is necessary at the time based on available information. Bavencio (avelumab) Imfinzi (durvalumab) Keytruda (pembrolizumab) Libtayo (cemiplimab-rwlc) Opdivo (nivolumab) Tecentriq (atezolizumab) Cholangitis sclerosing The "Adverse Reactions" section of the Keytruda (pembrolizumab) labeling was updated in August 2021 to include sclerosing cholangitis. Example: Keytruda labeling FDA determined that no action is necessary at the time for Bavencio (avelumab), Imfinzi (durvalumab), Libtayo (cemiplimab-rwlc), Opdivo (nivolumab), and Tecentriq (atezolizumab) based on available information. Chloroquine Generic products containing chloroquine Phospholipidosis The “Warnings” section of the labeling was updated in May 2022 to include information about phospholipidosis. Eliquis (apixaban) Pradaxa (dabigatran etexilate mesylate) Savaysa (edoxaban tosylate) Xarelto (ribaroxaban) Generic products containing dabigatran etexilate mesylate Generic products containing ribaroxaban Menorrhagia The “Use in Specific Populations” section was updated April 2021 to add language to describe the risk of clinically significant uterine bleeding in females of reproductive potential. Eliquis label Pradaxa label Savaysa label Xarelto label Depakote (divalproex sodium) Depakote ER (divalproex sodium) Stavzor (valproic acid) Generic products containing divalproex sodium Generic products containing valproic acid Tubulointerstitial nephritis The "Adverse Reactions" section of the labeling was updated in November 2021 to include tubulointerstitial nephritis. Example: Depakote labeling Dupixent (dupilumab) Alopecias FDA is evaluating the need for regulatory action. H.P. Acthar Gel (corticotropin) Anaphylactic and anaphylactoid responses The "Warnings and Precautions" and "Adverse Reactions" sections of the labeling were updated in October 2021 to include anaphylaxis. Acthar Gel labeling H.P. Acthar Gel (corticotropin) Cardiac arrhythmias The "Warnings and Precautions" and "Adverse Reactions" sections of the labeling were updated in October 2021 to include atrial fibrillations and palpitations. Acthar Gel labeling Ibrance (palbociclib) Kisqali (ribociclib) Kisqali Femara Co-Pack (letrozole and ribociclib) Verzenio (abemaciclib) Second primary malignancy FDA determined that no action is necessary at the time based on available information. Lynparza (olaparib) Drug-induced liver injury FDA determined that no action is necessary at the time based on available information. Ocrevus (ocrelizumab) Autoimmune colitis The "Warnings and Precautions", "Adverse Reactions", "Patient Counseling Information", and "Medication Guide" sections of the labeling were updated in August 2022 to include colitis. Ocrevus labeling Poteligeo (mogamulizumab-kpkc) Acute kidney injury The "Warnings and Precautions" section of the labeling was updated in March 2022 to include glomerulonephritis. Poteligeo labeling Ravicti (glycerol phenylbutyrate) Product labeling issue regarding stability and instructions for administration The container label, carton label, "Medication Guide", and sections of the Prescribing Information ("Dosage and Administration" and "Patient Counseling Information") were updated in September 2021 to enhance the instructions for administration. Ravicti labeling Spravato (esketamine) Hypertensive crisis FDA determined that no action is necessary at the time based on available information. Tremfya (guselkumab) Device use errors resulting in possible missed or partial doses The Tremfya One Press Instructions for Use (IFU) and carton labeling was updated in June 2023 to mitigate medication errors, such as underdose or no dose delivered. Tremfya labeling Trulance (plecanatide) Drug hypersensitivity The “Adverse Reactions” section of the Trulance labeling was updated April 2021 to include skin itching, hives, and rash. Trulance Label Trulance (plecanatide) Vomiting The “Adverse Reactions” section of the Trulance labeling was updated April 2021 to include vomiting. Trulance Label Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Drug Approval

29 Aug 2025

·www.einpresswire.com

April - June 2021 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)

Adcetris (brentuximab vedotin) Guillain-Barre syndrome FDA determined that no action is necessary at the time based on available information. Arzerra (ofatumumab) Gazyva (obinutuzumab) Riabni (rituximab-arrx) Rituxan (rituximab) Rituxan Hycela (rituximab and hyaluronidase human) Ruxience (rituximab-pvvr) Truxima (rituximab-abbs) Colitis FDA determined that no action is necessary at the time based on available information. Balversa (erdafitinib) Calciphylaxis The "Warnings and Precautions", "Patient Counseling Information", and the "Patient Information" sections of the labeling were updated in April 2022 to include information about soft tissue mineralization, including calciphylaxis. Balversa labeling Bavencio (avelumab) Keytruda (pembrolizumab) Opdivo (nivolumab) Yervoy (ipilimumab) Imfinzi (durvalumab) * Necrotizing fasciitis FDA determined that no action is necessary at this time based on available information. *An administrative error resulted in the omission of Imfinzi (durvalumab) from the list of product names. Imfinzi was added after the initial quarterly report was posted. Beta-blockers Betapace (sotalol hydrochloride) Brevibloc (esmolol hydrochloride) Bystolic (nebivolol) Byvalson (nebivolol and valsartan) Coreg (carvedilol) Coreg CR (carvedilol) Corgard (nadolol) Corzide (nadolol and bendroflumethiazide) Dutoprol (metoprolol succinate and hydrochlorothiazide) Kapspargo Sprinkle (metoprolol succinate) Lopressor HCT (metoprolol tartrate and hydrochlorothiazide) Sectral (acebutolol hydrochloride) Sotylize (sotalol hydrochloride) Tenoretic (atenolol and chlorthalidone) Toprol XL (metoprolol succinate) Trandate (labetalol hydrochloride) Ziac (bisoprolol fumarate and hydrochlorothiazide) Generic products containing beta-blockers Hemangeol (Propranolol Hydrochloride)* Inderal LA (Propranolol Hydrochloride)* Innopran XL (Propranolol hydrochloride)* Lopressor (metoprolol tartrate)* Tenormin (Atenolol)* Hypoglycemia in pediatric patients The "Warnings and Precautions" and "Patient Counseling Information" sections of the labeling were updated between March 2023 and June 2024 to add additional information regarding hypoglycemia. Example: Coreg labeling An administrative error resulted in the inclusion of Betapace AF, Levatol, and Zebeta in the list of product names at the time of the initial quarterly posting. *An administrative error resulted in the omission of Hemangeol, Inderal LA, Innopran XL, Lopressor, and Tenormin from the list of product names and was added after the initial quarterly report was posted. Bosulif (bosutinib monohydrate) Gleevec (imatinib mesylate) Iclusig (ponatinib) Sprycel (dasatinib) Tasigna (nilotinib) Osteonecrosis The "Adverse Reactions" section of the Tasigna labeling was updated in February 2024 to include information about osteonecrosis. Tasigna labeling FDA determined that Gleevec and Sprycel are adequately labeled for osteonecrosis, and that no further regulatory action is needed at this time. FDA determined no action is necessary at this time for Iclusig and Bosulif based on available information. Cablivi (caplacizumab-yhdp) Hemorrhage The "Warnings and Precautions", "Drug Interactions", and "Patient Counseling Information" sections of the labeling were updated in February 2022 to include information about life-threatening and fatal bleeding. Cablivi labeling Cyramza (ramucirumab) Cardiac failure The "Adverse Reactions" section of the labeling was updated in March 2022 to include information about heart failure. Cyramza labeling Doxil (doxorubicin hydrochloride) Acute interstitial pneumonitis FDA determined that no action is necessary at the time based on available information. Gleevec (imatinib mesylate) Tasigna (nilotinib) Myasthenia gravis FDA determined that no action is necessary at the time based on available information. Ibrance (palbociclib) Kisqali (ribociclib) Kisqali Femara Co-Pack (ribociclib; letrozole) Verzenio (abemaciclib) Radiation recall phenomenon FDA determined that no action is necessary at the time based on available information. Lokelma (sodium zirconium cyclosilicate) Gastrointestinal disorders FDA determined that no action is necessary at the time based on available information. Padcev (enfortumab vedotin-ejfv) Pancreatitis FDA determined that no action is necessary at the time based on available information. Padcev (enfortumab vedotin-ejfv) Pneumonitis The "Adverse Reactions", "Warnings and Precautions", and "Patient Counseling Information" sections of the labeling were updated in July 2021 to include information about pneumonitis. Padcev labeling Poteligeo (mogamulizumab-kpkc) Cytomegalovirus viraemia The "Adverse Reactions" section of the labeling was updated in March 2022 to include cytomegalovirus infection. Poteligeo labeling Procysbi (cysteamine bitartrate) Generic products containing cysteamine bitartrate Fibrosing colonopathy The "Warnings and Precautions", "Adverse Reactions", "Patient Information", and "Patient Counseling Information" sections of the labeling were updated in February 2022 to include information about fibrosing colonopathy. Example: Procysbi labeling Sarclisa (isatuximab-irfc) Herpes zoster The "Dosage and Administration", "Adverse Reactions", and "Patient Information" sections of the labeling were updated in July 2022 to include information about herpes zoster. Sarclisa labeling Sprycel (dasatinib) Drug-induced liver injury The “Warnings and Precautions”, “Adverse Reactions”, “Patient Counseling Information” and “Patient Information” sections of the labeling were updated in February 2023 to include information about hepatotoxicity. Sprycel labeling Taxotere (docetaxel) Rhabdomyolysis FDA determined that no action is necessary at the time based on available information. Veklury (remdesivir) Bradycardia FDA determined that no action is necessary at the time based on available information. Zepzelca (lurbinectedin) Extravasation The "Warnings and Precautions", "Adverse Reactions", "Patient Counseling Information", and "Patient Information" sections of the labeling were updated in April 2022 to include information about extravasation. Zepzelca labeling Zepzelca (lurbinectedin) Tumor lysis syndrome The “Adverse Reactions” section of the labeling was updated in April 2022 to include tumor lysis syndrome. Zepzelca labeling Zepzelca (lurbinectedin) Rhabdomyolysis The “Warnings and Precautions”, “Adverse Reactions”, “Patient Counseling Information”, and “Patient Information” sections of the labeling were updated in April 2022 to include rhabdomyolysis. Zepzelca labeling Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Drug Approval

24 Jul 2025

·pharma.economictimes.indiatimes.com

Lupin's US arm orders recall of over 58k bottles of hypertension drug

New Delhi: Generics drugmaker Lupin Limited US-arm Lupin Pharmaceuticals is recalling over 58000 bottles of ‘ Lisinopril and Hydrochlorothiazide ’ tablets due to a ‘product Mix Up issue’. According to the USFDA latest enforcement report the company has ordered a voluntary recall of 58,968 bottles of Lisinopril and Hydrochlorothiazide manufactured at the company Nagpur-based facility in India. “This product is being recalled because of a complaint received that a sealed bottle of lisinopril and hydrochlorothiazide tablets 20mg/12.5 mg had a foreign tablet identified as Atazanavir and Ritonavir tablet 300mg/100mg,” the report noted. The ongoing voluntary action is classified as a Class II recall, initiated by the company on June 20, 2025. According to the FDA, a Class II recall is a situation where the probability of serious adverse health consequences is remote and use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences. Lupin’s Lisinopril and Hydrochlorothiazide tablet is a Fixed-Dose Combination (FDC) of Lisinopril and Hydrochlorothiazide, indicated for the treatment of high blood pressure (hypertension). The drug inhibits angiotensin-converting enzyme (ACE) that helps relax blood vessels by blocking the formation of angiotensin II–a chemical that causes blood vessels to constrict–and its Hydrochlorothiazide ingredient is a thiazide diuretic that helps decrease blood volume by removing excess salt and water through the urine, thereby helping to reduce blood pressure. Lisinopril and Hydrochlorothiazide, is a popular hypertension medication marketed under both generic and branded by several drugmakers. By Online Bureau ,

100 Deals associated with Hydrochlorothiazide

External Link

KEGG	Wiki	ATC	Drug Bank
D00340	Hydrochlorothiazide	C03AA03	DB00999

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Nephrotic Syndrome	United States	Novitium Pharma LLC	28 Jan 2025
Diabetes Insipidus	China	Grand Pharmaceutical Group	01 Jan 1981
Edema	China	Yichang Humanwell Pharmaceuticals Co., Ltd.	01 Jan 1981
Nephrolithiasis	China	Tianjin Lisheng Pharmaceutical Co., Ltd.	01 Jan 1981
Hypertension	United States	Novartis Pharmaceuticals Corp.	12 Feb 1959

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Essential Hypertension	Phase 3	-	Boehringer Ingelheim GmbH	01 Jun 1998
Diabetes Mellitus, Type 2	Phase 2	Canada	Novartis Pharmaceuticals Canada, Inc.	01 Jan 2012

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02373163 (INTERVENCION Trial \| INTERVENCION, CTgov)	Phase 4	Hypertension	166	Hydrochlorothiazide (Diuretic)	sywgmfbbej(njczkgfgjt) = xootumuzid ownfsfvcre (gjsbjticxn, 8.4) View more	-	29 Jul 2025
				Amlodipine (Calcium-channel Blocker)	sywgmfbbej(njczkgfgjt) = ycjjmegsil ownfsfvcre (gjsbjticxn, 9.2) View more
NCT03295734 (ACES, CTgov)	Phase 2	Hypertension	223	Aerobic exercise+Perindopril (Perindopril)	pmgbfnqzjj(xjegifrtcd) = tiwcvkcwqu artrwbadxf (gjuejiivrk, tivkfpukik - bfssyfiddj) View more	-	22 Jul 2025
				Aerobic exercise+Losartan (Losartan)	pmgbfnqzjj(xjegifrtcd) = hwhlmdqcyy artrwbadxf (gjuejiivrk, stdmdvhxga - uruqeecdtr) View more
NCT00690521 (CTgov)	Not Applicable	Heart Failure \| Chronic congestive heart failure	8	Arm1+Hydrochlorothiazide+Metolazone+Furosemide (Arm1- Furosemide and Hydrochlorothiazide Then Furosemide + Metolazone)	jwuirpmcjl = egwsfjuzhq nuujzynkqp (gxrdphlwgb, yicbxaukof - rlwkblgigc) View more	-	10 Oct 2024
				Arm2+Hydrochlorothiazide+Metolazone+Furosemide (Arm2-Furosemide and Metolazone Then Furosemide and Hydrochlorothiazide)	jwuirpmcjl = yypmmofrka nuujzynkqp (gxrdphlwgb, xqdblmrzjd - ilbvmcuzgs) View more
NCT02185417 (Diuretic Comparison Project (DCP), Pubmed \| JAMA Netw Open) Manual	Phase 3	Hypertension	13,523	Chlorthalidone (with prior MI or stroke at baseline)	pqdiffgaqo(apspkgcnad) = fokvbliyit aobdmkpujx (cpyfdkhdog ) View more	Positive	01 May 2024
				Hydrochlorothiazide (with prior MI or stroke at baseline)	pqdiffgaqo(apspkgcnad) = kfcvjlmtzx aobdmkpujx (cpyfdkhdog ) View more
NCT03057431 (NOSTONE, CTgov)	Phase 3	Kidney Calculi	416	Placebo oral capsule (Placebo)	vqxakokegm = uygndtualq wosifmyfyn (htxwjoujxh, avvoaojmrv - ecuhhhrjtp) View more	-	01 Feb 2024
				12.5 mg hydrochlorothiazide (12.5 mg Hydrochlorothiazide)	vqxakokegm = pfjxnsjvnt wosifmyfyn (htxwjoujxh, lmozefxhmd - nlicxytxae) View more
NCT01647932 (CLOROTIC, Pubmed) Manual	Phase 3	Acute decompensated heart failure	230	Placebo	dtxshkafgo(ykbmbjtkqa) = The addition of HCTZ to furosemide was associated to a greatest weight loss at 72/96 h, better metrics of diuretic response and higher 24-h diuresis compared to placebo without significant differences according to sex mhquzgceif (bfuulyketk ) View more	Positive	11 Jan 2024
				furosemide+hydrochlorothiazide
NCT04334824 (Pubmed)	Not Applicable	Melanoma \| Carcinoma	2,953,748	Hydrochlorothiazide	czrqxomvpo(xqqupknuxt): HR = 1.12 (95% CI, 1.03 - 1.21), P-Value = ≥10 years	Negative	25 Apr 2023
				Angiotensin-converting enzyme inhibitors (ACEIs)
NCT03461003 (NICHE, CTgov)	Phase 4	Hypertension	49	NICHE method+Lisinopril+Hydrochlorothiazide+Amlodipine+Losartan (NICHE Method)	tnmbromqcd(klntstvfmy) = awlwyqrild jfdrxlehuo (eurjokxzeh, 9.301) View more	-	09 Sep 2022
				Usual care (Usual Care)	tnmbromqcd(klntstvfmy) = qbyhzlvkgw jfdrxlehuo (eurjokxzeh, 9.586) View more
NCT00667719 (CTgov)	Phase 3	Essential Hypertension	564	Hydrochlorothiazide+Aliskiren+Amlodipine	gyggcbahti(yxagverxhz) = nnpgnhynkf hztvifimlo (zcuoqaqxxc, 7.74) View more	-	07 Jun 2021
NCT02699125 (guanhctz, CTgov)	Phase 4	Sleep Apnea, Obstructive \| Hypertension	41	Placebo (Placebo)	khmafzdhgy(tzuovjvbjw) = jsdkuzpble mhzzjnxzeb (mhzqcwmjjl, 4.2) View more	-	04 Dec 2020
				Guanfacine (Guanfacine)	khmafzdhgy(tzuovjvbjw) = dgooypuuet mhzzjnxzeb (mhzqcwmjjl, 2.9) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis